Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis
Chapter 4: Blood Plasma Derivatives Market, by Type
4.1. Market Overview
4.1.1Market Size and Forecast, by Type
4.2. Albumin
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.3. Factor Viii
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
4.4. Factor Ix
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Share Analysis, by Country
4.5. Immunoglobulin
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Share Analysis, by Country
4.6. Hyperimmune Globulin
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Share Analysis, by Country
4.7. Others
4.7.1. Key Market Trends, Growth Factors and Opportunities
4.7.2. Market Size and Forecast, by Region
4.7.3. Market Share Analysis, by Country
Chapter 5: Blood Plasma Derivatives Market, by Application
5.1. Market Overview
5.1.1Market Size and Forecast, by Application
5.2. Hemophilia
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Share Analysis, by Country
5.3. Hypogammaglobulinemia
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, by Region
5.3.3. Market Share Analysis, by Country
5.4. Immunodeficiency Diseases
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, by Region
5.4.3. Market Share Analysis, by Country
5.5. Von Willebrand's Disease
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, by Region
5.5.3. Market Share Analysis, by Country
5.6. Other Application
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, by Region
5.6.3. Market Share Analysis, by Country
Chapter 6: Blood Plasma Derivatives Market, by End-user
6.1. Market Overview
6.1.1Market Size and Forecast, by End-user
6.2. Hospitals
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, by Region
6.2.3. Market Share Analysis, by Country
6.3. Clinics
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, by Region
6.3.3. Market Share Analysis, by Country
6.4. Other End-users
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, by Region
6.4.3. Market Share Analysis, by Country
Chapter 7: Blood Plasma Derivatives Market, by Region
7.1. Market Overview
7.1.1Market Size and Forecast, by Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, by Type
7.2.3. Market Size and Forecast, by Application
7.2.4. Market Size and Forecast, by End-user
7.2.5. Market Size and Forecast, by Country
7.2.6. United States Blood Plasma Derivatives Market
7.2.6.1. Market Size and Forecast, by Type
7.2.6.2. Market Size and Forecast, by Application
7.2.6.3. Market Size and Forecast, by End-user
7.2.7. Canada Blood Plasma Derivatives Market
7.2.7.1. Market Size and Forecast, by Type
7.2.7.2. Market Size and Forecast, by Application
7.2.7.3. Market Size and Forecast, by End-user
7.2.8. Mexico Blood Plasma Derivatives Market
7.2.8.1. Market Size and Forecast, by Type
7.2.8.2. Market Size and Forecast, by Application
7.2.8.3. Market Size and Forecast, by End-user
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, by Type
7.3.3. Market Size and Forecast, by Application
7.3.4. Market Size and Forecast, by End-user
7.3.5. Market Size and Forecast, by Country
7.3.6. Germany Blood Plasma Derivatives Market
7.3.6.1. Market Size and Forecast, by Type
7.3.6.2. Market Size and Forecast, by Application
7.3.6.3. Market Size and Forecast, by End-user
7.3.7. France Blood Plasma Derivatives Market
7.3.7.1. Market Size and Forecast, by Type
7.3.7.2. Market Size and Forecast, by Application
7.3.7.3. Market Size and Forecast, by End-user
7.3.8. U. K Blood Plasma Derivatives Market
7.3.8.1. Market Size and Forecast, by Type
7.3.8.2. Market Size and Forecast, by Application
7.3.8.3. Market Size and Forecast, by End-user
7.3.9. Italy Blood Plasma Derivatives Market
7.3.9.1. Market Size and Forecast, by Type
7.3.9.2. Market Size and Forecast, by Application
7.3.9.3. Market Size and Forecast, by End-user
7.3.10. Spain Blood Plasma Derivatives Market
7.3.10.1. Market Size and Forecast, by Type
7.3.10.2. Market Size and Forecast, by Application
7.3.10.3. Market Size and Forecast, by End-user
7.3.11. Rest of Europe Blood Plasma Derivatives Market
7.3.11.1. Market Size and Forecast, by Type
7.3.11.2. Market Size and Forecast, by Application
7.3.11.3. Market Size and Forecast, by End-user
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, by Type
7.4.3. Market Size and Forecast, by Application
7.4.4. Market Size and Forecast, by End-user
7.4.5. Market Size and Forecast, by Country
7.4.6. Japan Blood Plasma Derivatives Market
7.4.6.1. Market Size and Forecast, by Type
7.4.6.2. Market Size and Forecast, by Application
7.4.6.3. Market Size and Forecast, by End-user
7.4.7. China Blood Plasma Derivatives Market
7.4.7.1. Market Size and Forecast, by Type
7.4.7.2. Market Size and Forecast, by Application
7.4.7.3. Market Size and Forecast, by End-user
7.4.8. India Blood Plasma Derivatives Market
7.4.8.1. Market Size and Forecast, by Type
7.4.8.2. Market Size and Forecast, by Application
7.4.8.3. Market Size and Forecast, by End-user
7.4.9. Australia Blood Plasma Derivatives Market
7.4.9.1. Market Size and Forecast, by Type
7.4.9.2. Market Size and Forecast, by Application
7.4.9.3. Market Size and Forecast, by End-user
7.4.10. South Korea Blood Plasma Derivatives Market
7.4.10.1. Market Size and Forecast, by Type
7.4.10.2. Market Size and Forecast, by Application
7.4.10.3. Market Size and Forecast, by End-user
7.4.11. Rest of Asia-Pacific Blood Plasma Derivatives Market
7.4.11.1. Market Size and Forecast, by Type
7.4.11.2. Market Size and Forecast, by Application
7.4.11.3. Market Size and Forecast, by End-user
7.5. Lamea
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, by Type
7.5.3. Market Size and Forecast, by Application
7.5.4. Market Size and Forecast, by End-user
7.5.5. Market Size and Forecast, by Country
7.5.6. Brazil Blood Plasma Derivatives Market
7.5.6.1. Market Size and Forecast, by Type
7.5.6.2. Market Size and Forecast, by Application
7.5.6.3. Market Size and Forecast, by End-user
7.5.7. South Africa, Blood Plasma Derivatives Market
7.5.7.1. Market Size and Forecast, by Type
7.5.7.2. Market Size and Forecast, by Application
7.5.7.3. Market Size and Forecast, by End-user
7.5.8. Saudi Arabia Blood Plasma Derivatives Market
7.5.8.1. Market Size and Forecast, by Type
7.5.8.2. Market Size and Forecast, by Application
7.5.8.3. Market Size and Forecast, by End-user
7.5.9. Rest of LAMEA Blood Plasma Derivatives Market
7.5.9.1. Market Size and Forecast, by Type
7.5.9.2. Market Size and Forecast, by Application
7.5.9.3. Market Size and Forecast, by End-user
Chapter 8: Company Profiles
8.1. Bayer AG
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Biotest AG
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Csl Limited
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Fusion Health Care Pvt. Ltd
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Kedrion Biopharma ,Inc.
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Lfb S. A
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Octapharma AG
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Takeda
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Sanofi
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Grifols
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
List of Tables
Table 1. Global Blood Plasma Derivatives Market, by Type, 2020-2030 ($Million)
Table 2. Global Blood Plasma Derivatives Market for Albumin, by Region, 2020-2030 ($Million)
Table 3. Global Blood Plasma Derivatives Market for Factor Viii, by Region, 2020-2030 ($Million)
Table 4. Global Blood Plasma Derivatives Market for Factor Ix, by Region, 2020-2030 ($Million)
Table 5. Global Blood Plasma Derivatives Market for Immunoglobulin, by Region, 2020-2030 ($Million)
Table 6. Global Blood Plasma Derivatives Market for Hyperimmune Globulin, by Region, 2020-2030 ($Million)
Table 7. Global Blood Plasma Derivatives Market for Others, by Region, 2020-2030 ($Million)
Table 8. Global Blood Plasma Derivatives Market, by Application, 2020-2030 ($Million)
Table 9. Global Blood Plasma Derivatives Market for Hemophilia, by Region, 2020-2030 ($Million)
Table 10. Global Blood Plasma Derivatives Market for Hypogammaglobulinemia, by Region, 2020-2030 ($Million)
Table 11. Global Blood Plasma Derivatives Market for Immunodeficiency Diseases, by Region, 2020-2030 ($Million)
Table 12. Global Blood Plasma Derivatives Market for Von Willebrand's Disease, by Region, 2020-2030 ($Million)
Table 13. Global Blood Plasma Derivatives Market for Other Application, by Region, 2020-2030 ($Million)
Table 14. Global Blood Plasma Derivatives Market, by End-user, 2020-2030 ($Million)
Table 15. Global Blood Plasma Derivatives Market for Hospitals, by Region, 2020-2030 ($Million)
Table 16. Global Blood Plasma Derivatives Market for Clinics, by Region, 2020-2030 ($Million)
Table 17. Global Blood Plasma Derivatives Market for Other End-users, by Region, 2020-2030 ($Million)
Table 18. Global Blood Plasma Derivatives Market, by Region, 2020-2030 ($Million)
Table 19. North America Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 20. North America Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 21. North America Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 22. United States Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 23. United States Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 24. United States Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 25. Canada Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 26. Canada Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 27. Canada Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 28. Mexico Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 29. Mexico Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 30. Mexico Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 31. Europe Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 32. Europe Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 33. Europe Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 34. Germany Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 35. Germany Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 36. Germany Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 37. France Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 38. France Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 39. France Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 40. United Kingdom Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 41. United Kingdom Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 42. United Kingdom Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 43. Italy Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 44. Italy Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 45. Italy Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 46. Spain Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 47. Spain Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 48. Spain Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 49. Rest of Europe Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 50. Rest of Europe Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 51. Rest of Europe Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 52. Asia-Pacific Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 53. Asia-Pacific Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 54. Asia-Pacific Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 55. Japan Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 56. Japan Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 57. Japan Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 58. China Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 59. China Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 60. China Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 61. India Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 62. India Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 63. India Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 64. Australia Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 65. Australia Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 66. Australia Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 67. South Korea Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 68. South Korea Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 69. South Korea Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 70. Rest of Asia-Pacific Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 71. Rest of Asia-Pacific Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 72. Rest of Asia-Pacific Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 73. LAMEA Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 74. LAMEA Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 75. LAMEA Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 76. Brazil Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 77. Brazil Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 78. Brazil Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 79. South Africa, Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 80. South Africa, Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 81. South Africa, Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 82. Saudi Arabia Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 83. Saudi Arabia Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 84. Saudi Arabia Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 85. Rest of LAMEA Blood Plasma Derivatives, by Type, 2020-2030 ($Million)
Table 86. Rest of LAMEA Blood Plasma Derivatives, by Application, 2020-2030 ($Million)
Table 87. Rest of LAMEA Blood Plasma Derivatives, by End-user, 2020-2030 ($Million)
Table 88. Bayer Ag: Key Executives
Table 89. Bayer Ag: Company Snapshot
Table 90. Bayer Ag: Operating Segments
Table 91. Bayer Ag: Product Portfolio
Table 92. Bayer Ag: Key Strategic Moves and Developments
Table 93. Biotest Ag: Key Executives
Table 94. Biotest Ag: Company Snapshot
Table 95. Biotest Ag: Operating Segments
Table 96. Biotest Ag: Product Portfolio
Table 97. Biotest Ag: Key Strategic Moves and Developments
Table 98. Csl Limited: Key Executives
Table 99. Csl Limited: Company Snapshot
Table 100. Csl Limited: Operating Segments
Table 101. Csl Limited: Product Portfolio
Table 102. Csl Limited: Key Strategic Moves and Developments
Table 103. Fusion Health Care Pvt. Ltd: Key Executives
Table 104. Fusion Health Care Pvt. Ltd: Company Snapshot
Table 105. Fusion Health Care Pvt. Ltd: Operating Segments
Table 106. Fusion Health Care Pvt. Ltd: Product Portfolio
Table 107. Fusion Health Care Pvt. Ltd: Key Strategic Moves and Developments
Table 108. Kedrion Biopharma ,Inc. : Key Executives
Table 109. Kedrion Biopharma ,Inc. : Company Snapshot
Table 110. Kedrion Biopharma ,Inc. : Operating Segments
Table 111. Kedrion Biopharma ,Inc. : Product Portfolio
Table 112. Kedrion Biopharma ,Inc. : Key Strategic Moves and Developments
Table 113. Lfb S. A: Key Executives
Table 114. Lfb S. A: Company Snapshot
Table 115. Lfb S. A: Operating Segments
Table 116. Lfb S. A: Product Portfolio
Table 117. Lfb S. A: Key Strategic Moves and Developments
Table 118. Octapharma Ag: Key Executives
Table 119. Octapharma Ag: Company Snapshot
Table 120. Octapharma Ag: Operating Segments
Table 121. Octapharma Ag: Product Portfolio
Table 122. Octapharma Ag: Key Strategic Moves and Developments
Table 123. Takeda: Key Executives
Table 124. Takeda: Company Snapshot
Table 125. Takeda: Operating Segments
Table 126. Takeda: Product Portfolio
Table 127. Takeda: Key Strategic Moves and Developments
Table 128. Sanofi: Key Executives
Table 129. Sanofi: Company Snapshot
Table 130. Sanofi: Operating Segments
Table 131. Sanofi: Product Portfolio
Table 132. Sanofi: Key Strategic Moves and Developments
Table 133. Grifols: Key Executives
Table 134. Grifols: Company Snapshot
Table 135. Grifols: Operating Segments
Table 136. Grifols: Product Portfolio
Table 137. Grifols: Key Strategic Moves and Developments
List of Figures
Figure 1. Global Blood Plasma Derivatives Market Segmentation
Figure 2. Global Blood Plasma Derivatives Market
Figure 3. Segmentation Blood Plasma Derivatives Market
Figure 4. Top Investment Pocket in Blood Plasma Derivatives Market
Figure 5. Top Winning Strategies, 2019-2021*
Figure 6. Top Winning Strategies, by Development, 2019-2021(%)
Figure 7. Top Winning Strategies, by Company, 2019-2021*
Figure 8. Moderate Bargaining Power of Buyers
Figure 9. Moderate Bargaining Power of Suppliers
Figure 10. Moderate Threat of New Entrants
Figure 11. Low Threat of Substitution
Figure 12. High Competitive Rivalry
Figure 13. Top Player Positioning, 2020
Figure 14. Market Share Analysis, 2020
Figure 15. Restraints and Drivers: Blood Plasma Derivatives Market
Figure 16. Blood Plasma Derivatives Market Segmentation, by Type
Figure 17. Blood Plasma Derivatives Market for Albumin, by Country, 2020-2030 ($ Million)
Figure 18. Blood Plasma Derivatives Market for Factor Viii, by Country, 2020-2030 ($ Million)
Figure 19. Blood Plasma Derivatives Market for Factor Ix, by Country, 2020-2030 ($ Million)
Figure 20. Blood Plasma Derivatives Market for Immunoglobulin, by Country, 2020-2030 ($ Million)
Figure 21. Blood Plasma Derivatives Market for Hyperimmune Globulin, by Country, 2020-2030 ($ Million)
Figure 22. Blood Plasma Derivatives Market for Others, by Country, 2020-2030 ($ Million)
Figure 23. Blood Plasma Derivatives Market Segmentation, by Application
Figure 24. Blood Plasma Derivatives Market for Hemophilia, by Country, 2020-2030 ($ Million)
Figure 25. Blood Plasma Derivatives Market for Hypogammaglobulinemia, by Country, 2020-2030 ($ Million)
Figure 26. Blood Plasma Derivatives Market for Immunodeficiency Diseases, by Country, 2020-2030 ($ Million)
Figure 27. Blood Plasma Derivatives Market for Von Willebrand's Disease, by Country, 2020-2030 ($ Million)
Figure 28. Blood Plasma Derivatives Market for Other Application, by Country, 2020-2030 ($ Million)
Figure 29. Blood Plasma Derivatives Market Segmentation, by End-user
Figure 30. Blood Plasma Derivatives Market for Hospitals, by Country, 2020-2030 ($ Million)
Figure 31. Blood Plasma Derivatives Market for Clinics, by Country, 2020-2030 ($ Million)
Figure 32. Blood Plasma Derivatives Market for Other End-users, by Country, 2020-2030 ($ Million)
Figure 33. Bayer Ag: Net Sales, 2018-2020 ($ Million)
Figure 34. Bayer Ag: Revenue Share, by Segment, 2020 (%)
Figure 35. Bayer Ag: Revenue Share, by Region, 2020 (%)
Figure 36. Biotest Ag: Net Sales, 2018-2020 ($ Million)
Figure 37. Biotest Ag: Revenue Share, by Segment, 2020 (%)
Figure 38. Biotest Ag: Revenue Share, by Region, 2020 (%)
Figure 39. Csl Limited: Net Sales, 2018-2020 ($ Million)
Figure 40. Csl Limited: Revenue Share, by Segment, 2020 (%)
Figure 41. Csl Limited: Revenue Share, by Region, 2020 (%)
Figure 42. Fusion Health Care Pvt. Ltd: Net Sales, 2018-2020 ($ Million)
Figure 43. Fusion Health Care Pvt. Ltd: Revenue Share, by Segment, 2020 (%)
Figure 44. Fusion Health Care Pvt. Ltd: Revenue Share, by Region, 2020 (%)
Figure 45. Kedrion Biopharma ,Inc: Net Sales, 2018-2020 ($ Million)
Figure 46. Kedrion Biopharma ,Inc: Revenue Share, by Segment, 2020 (%)
Figure 47. Kedrion Biopharma ,Inc: Revenue Share, by Region, 2020 (%)
Figure 48. Lfb S. A: Net Sales, 2018-2020 ($ Million)
Figure 49. Lfb S. A: Revenue Share, by Segment, 2020 (%)
Figure 50. Lfb S. A: Revenue Share, by Region, 2020 (%)
Figure 51. Octapharma Ag: Net Sales, 2018-2020 ($ Million)
Figure 52. Octapharma Ag: Revenue Share, by Segment, 2020 (%)
Figure 53. Octapharma Ag: Revenue Share, by Region, 2020 (%)
Figure 54. Takeda: Net Sales, 2018-2020 ($ Million)
Figure 55. Takeda: Revenue Share, by Segment, 2020 (%)
Figure 56. Takeda: Revenue Share, by Region, 2020 (%)
Figure 57. Sanofi: Net Sales, 2018-2020 ($ Million)
Figure 58. Sanofi: Revenue Share, by Segment, 2020 (%)
Figure 59. Sanofi: Revenue Share, by Region, 2020 (%)
Figure 60. Grifols: Net Sales, 2018-2020 ($ Million)
Figure 61. Grifols: Revenue Share, by Segment, 2020 (%)
Figure 62. Grifols: Revenue Share, by Region, 2020 (%)